AlzeCure Pharma (ALZCUR) Pareto Securities Capital Market Days presentation summary

Business overview and model

• Focuses on developing therapies for Alzheimer's disease and pain, targeting high unmet medical needs with significant market potential.

• Operates as a research and development company, advancing projects to early clinical phases before out-licensing or partnering.

• Three main platforms: Alzstatin (Alzheimer's), NeuroRestore (cognitive disorders), and Painless (pain management).

• Listed on Nasdaq First North Premier Growth Market, Sweden, with a strengthened cash position from rights issues and upfront payments.

Key transactions and financial highlights

• Secured two major out-licensing deals in 2026: Alzstatin to Eli Lilly and NeuroRestore to Quantum Cell, with combined deal value exceeding USD 3.2bn (excluding royalties).

• Received USD 22M in upfront payments in 2026, bolstering financial stability.

• Rights issue in July 2026 was heavily oversubscribed, raising MSEK 30.1.

• Additional grant of 27.5 MSEK (€2.5M) from the European Innovation Council for Alzheimer's trial.

Pipeline and clinical progress

• Alzstatin (ACD680) is a gamma-secretase modulator for Alzheimer's, out-licensed to Lilly with global rights and >USD 1bn deal value.

• NeuroRestore (ACD856) is a Trk-PAM for cognitive disorders, out-licensed to Quantum Cell with >USD 2.2bn deal value.

• Painless platform includes ACD137 (TrkA-NAM for osteoarthritic pain, preclinical) and ACD440 (TRPV1 antagonist for neuropathic pain, phase II).

• ACD440 granted orphan drug designation in US and EU for erythromelalgia, with positive phase II results.